BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...
The FDA has approved Apidra (insulin glulisine [rDNA origin] injection, from sanofi-aventis) for the treatment of type 1 diabetes in children ≥4 years old. This approval was based on a 26-week, ...
BRIDGEWATER, N.J. The Food and Drug Administration has approved Apidra, a drug for improving glycemic control in diabetic children aged 4 and older, manufacturer Sanofi-Aventis said Wednesday. The FDA ...
European Commission approves Apidra for diabetes Apidra has a rapid onset and short duration of action which allows covering the postprandial hyperglycaemic peaks. It should normally be used in ...
Approval of APIDRA® gives a shot-in-the-arm to treatment of diabetes, especially in countries like the UAE where diabetes prevalence is among the highest in the world Sanofi-aventis announced ...
The approval of Apidra (R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra (R) in comparison with insulin lispro, in 572 children and ...
April 22, 2004 — The U.S. Food and Drug Administration (FDA) has approved insulin glulisine injection for diabetes, triamcinolone acetonide nasal aerosol for allergic rhinitis, abacavir sulfate for ...
The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results